Literature DB >> 24804901

The early history of Stanford Immunology.

Patricia P Jones1, Leonore A Herzenberg.   

Abstract

From its 1960 beginnings in a pair of windowless Genetics Department laboratories under the Stanford Medical School Dean's Office to its current broad-based program, which joins faculty members from departments across the Medical School, the Stanford Immunology Program has played a central role in shaping both basic and clinical immunology thinking. In this article, we tell the story of the beginnings of this odyssey in a reminiscence-based format that brings the flavor of the time in the words of people who lived and built the history.

Entities:  

Mesh:

Year:  2014        PMID: 24804901     DOI: 10.1007/s12026-014-8518-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  56 in total

1.  A SINGLE GENE CONTROLLING HEMOLYTIC COMPLEMENT AND A SERUM ANTIGEN IN THE MOUSE.

Authors:  R P ERICKSON; D K TACHIBANA; L A HERZENBERG; L T ROSENBERG
Journal:  J Immunol       Date:  1964-04       Impact factor: 5.422

2.  Fluorescence-activated cell sorting.

Authors:  L A Herzenberg; R G Sweet; L A Herzenberg
Journal:  Sci Am       Date:  1976-03       Impact factor: 2.142

Review 3.  Path to clinical transplantation tolerance and prevention of graft-versus-host disease.

Authors:  Samuel Strober
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 4.  A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….

Authors:  Ron Levy
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

5.  Tolerance and chimerism after renal and hematopoietic-cell transplantation.

Authors:  John D Scandling; Stephan Busque; Sussan Dejbakhsh-Jones; Claudia Benike; Maria T Millan; Judith A Shizuru; Richard T Hoppe; Robert Lowsky; Edgar G Engleman; Samuel Strober
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

6.  Purification and characterization of mouse hematopoietic stem cells.

Authors:  G J Spangrude; S Heimfeld; I L Weissman
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

7.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

8.  Serologically defined and lymphocyte-defined components of the major histocompatibility complex in the mouse.

Authors:  F H Bach; M B Widmer; M L Bach; J Klein
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

9.  Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation.

Authors:  S Slavin; Z Fuks; H S Kaplan; S Strober
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

10.  The monoclonality of human B-cell lymphomas.

Authors:  R Levy; R Warnke; R F Dorfman; J Haimovich
Journal:  J Exp Med       Date:  1977-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.